← Eichor
Study identifier: NCT07154342 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

Condition: Allergic Rhinitis, Seasonal  ·  Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

PhasePhase 3
Planned participants150
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.

This description comes directly from the study's public registry record.

Talk to the study team

liaison officer  ·  021-50805988-8039  ·  fangxiaoyan@genrixbio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongnan Hospital of Wuhan universityWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07154342